General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Half-Life (Normalesrd) Hours
50-100/Unchanged
Plasma Protein Binding %
99
Volume Of Distribution L/Kg
0.09-0.17
Dose For Normal Renal Function
100 mg tid-qid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Aarbakke J. Clinical pharmacokinetics of phenylbutazone. Clin Pharmacokinet. 1978; 3: 369-80. [PMID: 359213]